Skip to main content
OpenTrials

Clinical trial condition

Primary Peritoneal Cancer

Explore clinical trials studying Primary Peritoneal Cancer. Study availability and eligibility vary by location and protocol.

91 public trials 21 recruiting studies
Refine in advanced search Browse all conditions

Primary Peritoneal Cancer trial results

Recruiting

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

NCT04657068

Conditions
Acinar Cell Carcinoma, Adenocarcinoma, Adnexal Diseases, +55 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Mayo Clinic (Arizona) Scottsdale, Arizona, United States
  • University of Arkansas - Winthrop P. Rockefeller Cancer Institute Little Rock, Arkansas, United States
  • USC Norris Comprehensive Cancer Center Los Angeles, California, United States
View all 82 locations
View Trial Details
Recruiting

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

NCT06890338

Conditions
Adnexal Diseases, Carcinoma, Carcinoma, Ovarian Epithelial, +22 more
Locations
  • University of Alabama at Birmingham (UAB) Hospital /ID# 274793 Birmingham, Alabama, United States
  • Usa Mitchell Cancer Institute /ID# 276022 Mobile, Alabama, United States
  • University of California Los Angeles Medical Center /ID# 274566 Los Angeles, California, United States
  • Scripps Md Anderson - Prebys Cancer Center /ID# 276891 San Diego, California, United States
View all 67 locations
View Trial Details
Recruiting

A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors

NCT06792552

Conditions
Adenocarcinoma, Adnexal Diseases, Advanced Solid Tumors, +35 more
Locations
  • Sarah Cannon Research Institute (SCRI) - Lake Nona Orlando, Florida, United States
  • Emory Winship Cancer Institute Atlanta, Georgia, United States
  • University Medical Center of New Orleans LSU-LCMC Health Cancer Center New Orleans, Louisiana, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
View all 17 locations
View Trial Details
Recruiting

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

NCT06824467

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +17 more
Locations
  • University of Alabama at Birmingham ( Site 0006) Birmingham, Alabama, United States
  • Alaska Women's Cancer Care ( Site 0096) Anchorage, Alaska, United States
  • UCSF Medical Center at Mission Bay ( Site 0013) San Francisco, California, United States
  • John Muir Health Cancer Center ( Site 0016) Walnut Creek, California, United States
View all 186 locations
View Trial Details
Recruiting

Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT04606914

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +15 more
Locations
  • University of Alabama at Birmingham Womens & Infants Center Birmingham, Alabama, United States
  • University of California San Francisco San Francisco, California, United States
  • University of Minnesota - Masonic Cancer Center Minneapolis, Minnesota, United States
  • Mayo Clinic Rochester, Minnesota, United States
View Trial Details
Recruiting

CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer

NCT07322094

Conditions
Adnexal Diseases, FIGO Stage III and IV Ovarian Cancer, Fallopian Tube Cancers, +12 more
Locations
  • Providence St. Jude Medical Center Fullerton, California, United States
  • City of Hope Irvine, California, United States
  • University of Southern California Los Angeles, California, United States
  • UCLA Los Angeles, California, United States
View Trial Details
Recruiting

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

NCT05281471

Conditions
Adnexal Diseases, DNA Virus Infections, Endocrine Gland Neoplasms, +26 more
Locations
  • The University of South Alabama, Mitchell Cancer Institute Mobile, Alabama, United States
  • University of Arizona Cancer Center Tucson, Arizona, United States
  • City of Hope Duarte, California, United States
  • UC San Diego Health - Moores Cancer Center La Jolla, California, United States
View all 32 locations
View Trial Details
Recruiting

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

NCT06787612

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +17 more
Locations
  • The University of Alabama at Birmingham Birmingham, Alabama, United States
  • UC San Diego Health La Jolla, California, United States
  • Cedars Sinai Medical Center Los Angeles, California, United States
  • Mayo Clinic Jacksonville Jacksonville, Florida, United States
View all 54 locations
View Trial Details

Related conditions